Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in IntangiblesChange in IntangiblesChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oculis Holding AG (OCS) Cash from Investing Activities (2022 - 2024)

Quarterly Cash from Investing Activities changed N/A to -$19.7 million in Q2 2024 from the year-ago period, while the trailing twelve-month figure was -$464875.5 through Jun 2024, changed N/A year-over-year, with the annual reading at -$76.2 million for FY2025, 315.26% down from the prior year.

Oculis Holding AG's Cash from Investing Activities history spans 3 years, with the latest figure at -$19.7 million for Q2 2024.

  • Cash from Investing Activities came in at -$19.7 million for Q2 2024, down from -$2.3 million in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $25.9 million in Q4 2023 to a low of -$19.7 million in Q2 2024.
  • The 3-year median for Cash from Investing Activities is -$2.0 million (2024), against an average of -$427938.7.
  • The largest YoY upside for Cash from Investing Activities was 1744.57% in 2023 against a maximum downside of 714.06% in 2023.
  • Oculis Holding AG's Cash from Investing Activities stood at -$1.6 million in 2022, then soared by 1744.57% to $25.9 million in 2023, then crashed by 176.04% to -$19.7 million in 2024.
  • Per Business Quant, the three most recent readings for OCS's Cash from Investing Activities are -$19.7 million (Q2 2024), -$2.3 million (Q1 2024), and $25.9 million (Q4 2023).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Investing Activities (Qtr)
1 Quantum Biopharma 1,384,976.65 Bn 1,384,976.64 Bn - -2.89 Mn
2 Alterity Therapeutics 777,208.84 Bn 777,208.81 Bn - -
3 Legend Biotech 2,801.00 Bn 2,800.10 Bn 242.10 Mn 638.50 Mn
4 Nanobiotix 2,226.01 Bn 2,225.95 Bn - -
5 Akari Therapeutics 605.66 Bn 605.66 Bn - -
6 Vertex Pharmaceuticals 110.17 Bn 102.92 Bn 2.59 Bn -431.90 Mn
7 Regeneron Pharmaceuticals 66.86 Bn 58.11 Bn 3.31 Bn -428.90 Mn
8 Evaxion A 65.12 Bn 65.10 Bn - -
9 Alnylam Pharmaceuticals 39.94 Bn 36.94 Bn 959.66 Mn -25.54 Mn
10 Oculis Holding AG 24.51 Bn 24.21 Bn - -

Historic Data

Download Data 🔒
DateValue
Jun 30, 2024 -19.67 Mn
Jun 30, 2024 -19.67 Mn
Mar 31, 2024 -2.35 Mn
Mar 31, 2024 -2.35 Mn
Dec 31, 2023 25.86 Mn
Dec 31, 2023 25.86 Mn
Sep 30, 2023 -4.32 Mn
Sep 30, 2023 -4.32 Mn
Dec 31, 2022 -1.57 Mn
Dec 31, 2022 -1.57 Mn
Sep 30, 2022 -530,153.80
Sep 30, 2022 -530,153.80